RxDoctor Payments Data

William Rusinow, MD

Family Medicine · Detroit, MINPI 1295118784

Payments from drug & device makers

$3,961in general payments, 2019–2025

Across 146 payments — averaging $27.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$766
  • AbbVie$185
  • Lilly USA, LLC$179
  • Axsome Therapeutics, Inc.$174
  • Exact Sciences$170
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,961100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,961 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$39,982
Medicare patients
106
Services billed
511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$101,652
OzempicSemaglutide83$91,952
EliquisApixaban77$73,838
TrulicityDulaglutide76$73,305
FarxigaDapagliflozin Propanediol76$64,814
JanuviaSitagliptin Phosphate74$57,941
JardianceEmpagliflozin57$55,990
MounjaroTirzepatide35$37,237
XareltoRivaroxaban28$30,414
Breo ElliptaFluticasone/Vilanterol39$19,628
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$16,649
EntrestoSacubitril/Valsartan11$10,173
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$9,113
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$9,049
Albuterol Sulfate HfaAlbuterol Sulfate241$7,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$138$125,458165 claims
Lilly USA, LLCTrulicity, Mounjaro$179$110,543111 claims
Novo NordiskOzempic$169$91,95283 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,374$84,029108 claims
PfizerEliquis$766$73,83877 claims
NovartisEntresto$67$10,17311 claims
Supernus Pharmaceuticals, Inc.Qelbree$59$6,65514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →